Carlo Lo Sterzo

Carlo Lo Sterzo has a diverse work experience in the field of scientific research and development. Carlo started their career at the University of Rome "La Sapienza" where they completed their PhD in Biochemistry. Following this, they worked as a Post Doctoral Scientist at UC Berkeley, focusing on the design and purification of engineered proteins and transcription factors for novel assays development. Carlo also served as a Laboratory Safety Manager during their time at UC Berkeley.

Carlo then joined GSK, where they held the positions of AS&T Chemistry Validation Specialist and Scientific Associate II in the Technical R&D Drug Substance department. In these roles, they validated analytical methods for glycoconjugate vaccines and provided troubleshooting support. Carlo also contributed to downstream process development for vaccine products, with a focus on improving purification processes using Quality by Design and DoE approaches.

After GSK, Carlo worked at MENARINI Group as a Scientist in the Technical Development Department. Their responsibilities included developing analytical methods for glycoconjugate vaccines and supporting manufacturing operations in a GMP environment. Carlo also played a role in writing and reviewing SOPs, TRs, and Deviation Reports.

Currently, Carlo is employed at Philogen S.p.A. as a Scientist in the Downstream Process Development, Optimization Department. In this position, they are responsible for designing, developing, and optimizing purification processes for monoclonal antibodies and recombinant therapeutic proteins. Their work involves initial process screening, column chromatography optimization, TFF set-up, and process yield implementation.

Throughout their career, Carlo Lo Sterzo has demonstrated expertise in purification processes, analytical method development, troubleshooting, and technical documentation.

Carlo Lo Sterzo pursued their educational journey by obtaining a Bachelor's degree in Biotechnologies from the University of Rome Tor Vergata. Carlo attended the university from 2002 to 2005. Subsequently, they pursued a Master's degree in Pharmaceutical Biotechnologies from Sapienza Università di Roma, completing their studies from 2006 to 2008.